Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ProKidney Corp. Skyrockets 515% on Trial Data, But is it a Buy? wealthyventurecapitalist.com - Wed Jul 9, 5:40AM CDT

Shares of ProKidney Corp. (NASDAQ: PROK) soared 515% on Tuesday, triggering shockwaves across Wall Street after the company unveiled highly promising Phase 2 trial results for its experimental kidney disease...

C : 87.08 (+1.50%)
BAC : 46.97 (+0.28%)
VRTX : 479.53 (+0.12%)
FGEN : 7.35 (+18.74%)
PROK : 5.18 (+19.35%)
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz Motley Fool - Tue Jul 8, 4:35PM CDT

VRTX : 479.53 (+0.12%)
FGEN : 7.35 (+18.74%)
PROK : 5.18 (+19.35%)
FibroGen Announces 1-for-25 Reverse Stock Split GlobeNewswire - Thu Jun 12, 3:02PM CDT

FGEN : 7.35 (+18.74%)
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors GlobeNewswire - Mon Jun 9, 3:02PM CDT

FGEN : 7.35 (+18.74%)
FibroGen: Q1 Earnings Snapshot AP - Mon May 12, 3:13PM CDT

FibroGen: Q1 Earnings Snapshot

FGEN : 7.35 (+18.74%)
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Mon May 12, 3:02PM CDT

FGEN : 7.35 (+18.74%)
FibroGen to Report First Quarter 2025 Financial Results GlobeNewswire - Mon May 5, 3:05PM CDT

FGEN : 7.35 (+18.74%)
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference GlobeNewswire - Wed Apr 2, 3:05PM CDT

FGEN : 7.35 (+18.74%)
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology GlobeNewswire - Fri Mar 28, 6:00AM CDT

FGEN : 7.35 (+18.74%)
FibroGen: Q4 Earnings Snapshot AP - Mon Mar 17, 3:28PM CDT

FibroGen: Q4 Earnings Snapshot

FGEN : 7.35 (+18.74%)

Barchart Exclusives

These 3 Bank Stocks Are Boosting Dividends. Should You Buy Them Here? Barchart - Thu Jul 10, 6:30PM CDT
Goldman Sachs, JPMorgan Chase, and Morgan Stanley are boosting dividends after passing the Fed’s 2025 stress test. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot